Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Geoffrey Ira Shapiro

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3331-4095; OpenAlex author ID A5045419282; NIH RePORTER profile ID 1941065. Sources: ClinicalTrials.gov.

Their work

Papers
7
Trials
2 (principal investigator on 2)
Grants
1
Labs led
1
Collaborators
32
Papers, trials and grants by year

2017: 2 trials · 2018: 1 paper · 2019: none · 2020: none · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 grant · 2026: 1 paper

Papers 7

  1. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
  2. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-3930↗
  3. A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancr… Co-author DOI 10.1158/1078-0432.ccr-23-2005↗
  4. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.11.017↗
  5. Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-1367↗
  6. Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment o… Co-author DOI 10.21037/jgo-21-197↗
  7. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Co-author DOI 10.1158/2159-8290.cd-18-0275↗

Trials 2

  1. Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamou… Principal investigator NCT03065062↗
  2. CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors Principal investigator NCT03113188↗

Grants 1

  1. Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers R01CA272982↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew J. Aguirre · 6 shared papers, 2021–2026 · strength 0.76
  2. Brian Matthew Wolpin · 6 shared papers, 2021–2026 · strength 0.76
  3. James M. Cleary · 6 shared papers, 2021–2026 · strength 0.76
  4. Harshabad Singh · 5 shared papers, 2021–2026 · strength 0.68
  5. Srivatsan Raghavan · 5 shared papers, 2021–2026 · strength 0.64
  6. Douglas Adam Rubinson · 5 shared papers, 2021–2026 · strength 0.64
  7. Kimberly J. Perez · 5 shared papers, 2021–2026 · strength 0.64
  8. Alan D. D’Andrea · 4 shared papers, 2021–2026 · strength 0.56
  9. Kimmie Ng · 4 shared papers, 2021–2026 · strength 0.52
  10. Jonathan Andrew Nowak · 4 shared papers, 2021–2026 · strength 0.51
  11. Brandon M. Huffman · 3 shared papers, 2021–2026 · strength 0.44
  12. Matthew B.B. Yurgelun · 3 shared papers, 2021–2026 · strength 0.43
  13. Leah H. Biller · 2 shared papers, 2023–2026 · strength 0.31
  14. Thomas E. Clancy · 2 shared papers, 2021–2023 · strength 0.20
  15. Mary Linton B. Peters · 1 shared paper, 2026 · strength 0.19
  16. Nadine A. Jackson · 1 shared paper, 2026 · strength 0.19
  17. Andrea J. Bullock · 1 shared paper, 2026 · strength 0.19
  18. ANDREA C Enzinger · 1 shared paper, 2026 · strength 0.19
  19. Thomas Adam Abrams · 1 shared paper, 2023 · strength 0.13
  20. Stephanie K. Dougan · 1 shared paper, 2021 · strength 0.12
  21. Chen Yuan · 1 shared paper, 2023 · strength 0.12
  22. Michael Hayden Rosenthal · 1 shared paper, 2023 · strength 0.12
  23. Julien Dilly · 1 shared paper, 2023 · strength 0.12
  24. Rishi Surana · 1 shared paper, 2023 · strength 0.12
  25. David P. Ryan · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.